GSK will acquire full global rights to CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager from Chimagen for USD300,000,000 upfront with additional success and milestone payments totalling up to USD550,000,000. GSK plans to develop and commercialise CMG1A46 with a focus on B cell-driven autoimmune diseases including lupus.
The Appleby team was led by David Bulley, Hong Kong and Mainland China Managing Partner, and included lawyers across the corporate and regulatory teams in Hong Kong, Shanghai and the Cayman Islands.
Commenting on the deal, David said: “Appleby continues to represent the world’s largest biopharma and pharmaceutical companies on the offshore aspects of their businesses and transactions. Our advice is sought out because of our understanding of the space and the commercial nature of our advice not only on transaction steps but also structuring solutions that we are able to provide from our senior-led, highly experienced deal teams.
“We look forward to continuing to assist clients in these key transactions that ultimately allow the development of improved medical treatments.”
